Reimbursed Care Access in Eswatini

Currently classified as a strictly controlled/habit‑forming drug under Eswatini's national drug control framework with no authorized medical use outside approved clinical research. The country's Opium and Habit‑forming Drugs Act (and related pharmacy scheduling provisions) criminalize dealing in and possession of ‘habit‑forming drugs’ and plants from which such drugs are derived, and the Pharmacy Act provides for scheduling of potentially harmful drugs that limits their supply to prescriptions or ministerial licence where permitted. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Opium and Habit‑forming Drugs Act and the Pharmacy Act provide the legal basis for prohibition and tightly restricted medical supply channels. # #.

There is no public record of national marketing authorization, routine clinical rollout, or reimbursement for intranasal esketamine (Spravato) in Eswatini. Globally, esketamine is distributed under product‑specific restrictions and REMS programs in jurisdictions where it is approved; Eswatini has no publicly available treatment‑center listing or regulatory approval entry for the product, and no evidence of a national reimbursement pathway. In practice, access would therefore be limited to formal clinical trials, importation under a ministerial/medical permit, or ad hoc compassionate/individual import mechanisms if granted. For manufacturer information about international availability limitations for Spravato, see the product resources noting limited public outside‑US rollout information. # #.

Ketamine is recognized and used in Eswatini as an essential anaesthetic/analgesic agent within hospital care (public and private) and therefore has an established medical supply pathway — it is dispensed and used under prescription/clinical direction in operating theatres and emergency settings. The Pharmacy Act frames the regulatory regime for potentially harmful drugs and prescription supply; practical reporting from Eswatini hospitals documents ketamine among essential anaesthetic injections and occasional national stock shortages, which demonstrates clinical reliance on the drug for standard medical indications (e.g., anaesthesia, emergency analgesia). Reimbursement: there is no published, comprehensive national reimbursement schedule specific to ketamine for psychiatric indications in Eswatini; when ketamine is provided as part of hospital inpatient or operative care it is typically covered through the hospital provisioning pathway (public hospitals supply medicines within budgetary constraints) or by private patient payment/insurance in private settings. There is no evidence of a structured, reimbursed ketamine‑assisted psychotherapy programme or national outpatient ketamine clinics with formal reimbursement. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Eswatini's Opium and Habit‑forming Drugs Act and Pharmacy Act provide the statutory basis for prohibition of narcotics/psychotropic substances and restrictive medical supply. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The statutory framework in Eswatini criminalizes dealing in and possession of habit‑forming drugs and plants from which such drugs are derived, which covers synthetic tryptamines such as 5‑MeO‑DMT. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no domestic regulatory pathway publicly documented for ibogaine therapy or reimbursement in Eswatini; possession, supply or cultivation related to habit‑forming substances is governed by national legislation. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While international treaty interpretation varies for plant/mixture preparations, Eswatini's domestic law broadly prohibits dealing in habit‑forming drugs and plants used to produce them; therefore ritual or ceremonial importation/possession would be legally exposed absent a specific ministerial permit or exemption for research. # # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. National statutes criminalize production, possession and supply of habit‑forming drugs and plants from which such drugs are derived, covering mescaline and mescaline‑containing cacti absent specific regulatory exemption. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamine analogues (the 2C family) are covered by the country's broad prohibitions on psychotropic and habit‑forming substances; there is no regulatory pathway for medical or reimbursed therapeutic access. # #.